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2A Well Known Story
 Hyperglycaemia is prevalent in critical care
 Impaired insulin production + Increased insulin resistance = High BG
 Average blood glucose values > 10mmol/L are not uncommon
 Higher mean, median and variation of BG all increase odds risk of death by 2-4x 
vs lower levels around 6 mmol/L and low variability
 Tight control  better outcomes:
 Reduced mortality ~17-43% (6.1-7.75 mmol/L) [van den Berghe, Krinsley]
 SPRINT reduces mortality 32-45% depending on LoS in ICU (details to come)
 Costly treatments & tests (mech. ventilation, transfusions, … ) are also reduced
 However, how to get this result w/o all the hypoglycemia and 
other difficult to repeat control issues
 SPRINT reduced hypoglycemia by 50%, others see 200-400% increases
 Model-based methods and engineering approach offer an answer
Between a rock and a hard place: 
Pitfalls or just a hard problem?
• Hypoglycaemia?
– Risk of neurological damage?
– Fear of hypoglycaemia?
• Lack of „buy-in‟ by physicians and nursing staff
• Hyperglycaemia?
– Patients evolve rapidly
– High insulin resistance and insulin requirements
– Insulin effect saturation
– Infrequent measurement  or  Burden
• Not doing anything …? Too hard?
The real question is how to manage the risk and reward 
in an optimal fashion for each patient.
The “rock”
The “hard place”
Our Approach – A fat man on a see-saw
• Nutritional Inputs
• Endogenous Glucose 
Production
• Exogenous Insulin
• Endogenous Insulin
• Non-insulin Removal
Rising 
Glucose
Falling Glucose
Semi-Automated feedback control
Standard infuser equipment
Identify and utilise 
patient specific 
parameters to 
optimise therapy
Patient management
Nursing Staff
Measured data Decision Support System
Minimal time & training – Minimal interruption – Easy to understand 
 Transparent
The Cohorts: Before/After Study
• Retrospective before-after study – 1.2 yr SPRINT vs 2.5 yr past
• ROD is higher for SPRINT
– Different case mix with retrospective cohort having much more 
cardiovascular surgery than recently (non-clinical causes)
• Otherwise statistically similar
– Retrospective more cardiovascular surgery so ROD likely lower again
– More similar for LoS > 2 days
 Overall 
 Retrospective SPRINT  
Total patients 516 394  
   p-value 
Age (years) 65  [53 - 74] 65 [50 – 74] 0.22 
% Male 60.1% 62.9% 0.38 
APACHE II score 19 [15 - 24] 18 [14 – 24] 0.06 
APACHE II risk of 
death 
24.1% [11.2% - 45.3%] 25.7% [13.3% - 48.1%] 0.19 
 
Admission: 2 BG > 8 mmol/L or 1 BG > 10 mmol/L
No exclusions
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Overall SPRINT Glycaemic control
Overall cohort data Retrospective SPRINT  
   Number of patients 516 394  
   Hours of control 62,769 47,290 hours 
   Total BG measurements 15,618 29,983  
   BG mean (lognormal) 7.3 6.0 mmol/L 
   BG standard deviation (lognormal) 2.4 1.5 mmol/L 
   Percentage of measurements between:    
      4.0 – 6.1 mmol/L 31.5% 59.2%  
      4.0 – 7.0 mmol/L 50.3% 79.1%  
      4.0 – 7.75 mmol/L 62.9% 86.5%  
   Percentage of measurements less than:    
      4.0 mmol/L 3.6% 3.9%  
      2.2 mmol/L 0.2% 0.1%  
   Mean insulin usage 1.0 2.9 U/hr 
   Mean nutrition rate    
      During periods of feeding 1611 1279 kcal/day 
      Entire duration of SPRINT usage - 1055 kcal/day 
   Mean % of goal feed - 66%  
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Nutrition and Insulin Concerns
Matches recent results where tight control via IIT decreased insulin required 
over days 2-7 and thus allows increased nutrition (Langouche et al, 2007)
Avg feed rate exceeded 
@ 2.8 days
Mean Insulin of 2.9 
U/hr most of time in 
days 1-5
• 1279 kcal/day  110g/day CHO
• In optimal middle tertile for ROD 
from Krishnan et al, 2005 study
• Nutrition is only useful if it is utilised
SPRINT stopped at 2U/hr 
and ~1300+ kcal/day
Focuses on increasing 
feed as possible using 
“moderate” insulin
SPRINT Glycaemic Control Per Patient
Per-patient data    
   Hours of control 57 [25 – 162] 53 [19 – 147] hours 
   Number of BG measurements 17 [8 – 40] 37 [16 – 97]  
   BG mean (lognormal) 7.5 [6.7 – 8.4] 6.0 [5.5 – 6.6] mmol/L 
   BG standard deviation (lognormal) 1.6 [1.2 – 2.4] 1.3 [1.0 – 1.8] mmol/L 
   Percentage of patients < 7 mmol/L 82% 99%  
   Percentage of patients < 6.1 mmol/L 73% 96%  
   Insulin usage 0.9 [0.1 – 1.6] 2.6 [2.1 – 3.3] U/hr 
   Nutrition rate    
      During periods of feeding 724 [0 – 1596] 938 [0 – 1304] kcal/day 
      Entire duration of SPRINT usage - 708 [0 – 1174] kcal/day 
   % of goal feed - 50% [0% - 71%]  
 
Retrospective SPRINT
• Tighter per patient std deviation – indicates each patient is tighter than the 
cohort to their patient specific mean
• Variability (std deviation) is 20% lower/tighter than retrospective
• Nutrition is actually higher (due to tighter control and less shutoff?)
• Feed shutoff for other clinical reasons can skew results
• Effectively all patients are brought under 7 mmol/L and 96% under 6.1 mmol/L
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Per-Patient cumulative BG distribution: median, IQR & 90% CI
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Is the total mortality of SPRINT patients against total number of patients 
Treated on the protocol
Nursing Feedback at 2 Months
Survey completed by 26 Christchurch Hospital ICU Nurses
Bottom line: Intuitive and easy for staff to use.
ICU staff workload reduced 
Compliance over 97% (dose)
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Burden Overall Transparency
But Why? The answer is by the SOFA!
• We examined daily SOFA score for every patient (ignored CNS score)
• Initial SOFA and maximum SOFA are similar and in a similar number of days
• So, how did TGC affect reduction of organ failure as reflected by SOFA 
score? Does SPRINT get patients organ failure down faster providing a better 
platform for (later) survival?
Table 2: Day 1 and Maximum total SOFA score for each cohort plus percent mortality 
and number of patients [died, lived] by maximum SOFA score range. 
 SPRINT Pre-SPRINT p-value 
Day 1 SOFA (Mean ± SD) 5.6 ± 2.8 5.4 ± 3.0 0.20 
Maximum SOFA (Mean ± SD) 6.8 ± 3.0 7.0 ± 3.2 0.76 
Day of Maximum SOFA score 
(Median [IQR]) 
1 [1, 3] 1 [1, 3] 0.99 
    
Mortality (%) [#Died, #Lived] 
by Maximum SOFA Range 
   
0-4  4.4%     [4, 86]  5.2%     [5, 92] 1.00 
5-9 14.2%    [30, 185] 15.3%    [36, 199] 0.70 
10-14 33.9%    [21, 41] 40.9%    [29,42] 0.47 
15-19 75.0%    [3, 1] 70.0%    [7, 3] 1.00 
    
The Answer?
• SOFA scores reduce faster with SPRINT and do so from day 2
• Organ failure free days: SPRINT = 41.6% > Retro = 36.6% (p<0.0001)
• Number of organ failures (% total possible) defined as SOFA > 2 for 1 
SOFA score component: SPRINT = 16% < Retro = 19% (p<0.0001)
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SPRINT
Pre-SPRINT
SPRINT-fitted to 28 days
Pre-SPRINT-fitted to 28 days
The impact on cost?
• Organ failures = increased cost due to increased need for care
• Therefore, cost should be lower (as seen in other studies)
$2M
$0.5M
$1.5M
Pre-SPRINTSPRINT
$2M
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$1 M
Cost per patient 
comparison between wards 
ICU cost comparison
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Cost was mostly saved in …
• Relatively well patients were most cost effective under SPRINT
SPRINT cost savings by 
max SOFA score
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The Future?
• Stochastic Targeted (STAR) glycemic control
• Model-based and computer driven
• Forecasts changes in patient-specific behaviour using 
validated models to provide guaranteed levels of 
safety from hypoglycemia!
• To be trialled in Christchurch and Liege, Belgium in 
2010.
Stochastic model in action
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Stochastic model in action
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Insulin sensitivity might not 
change much, so expect a 
~constant BG response
Stochastic model:
Stochastic model in action
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Insulin sensitivity might 
rise suddenly, so there is a 
possibility of lower BG
Stochastic model:
Stochastic model in action
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Insulin sensitivity might 
drop suddenly, so there 
may spike in BG
Stochastic model:
Stochastic model in action
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Work out the 90% 
confidence range for future 
insulin sensitivity and BG 
values
Stochastic model:
Stochastic model in action
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Forecasted BG values are 
used to make sure BG 
doesn’t go too low
Stochastic model:
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Kernel density model (lag-1)
1) Hourly changes in insulin sensitivity
2) Kernel density model
3) Conditional probability used for forecasting
4) Probability bounds for data set
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Kernel density model (lag-1)
• Likelihood of a future 
level of insulin sensitivity 
can be quantified
4) Probability bounds for data set
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So, what does it look like in action?
• STAR was trialled with a neonate specific model in the 
Christchurch NICU
• 8 patients have undergone 24 hour trials
• A further 8 have used system for entire length of hyperglycemia
• So, one example to show what a “STAR” glycemic controller 
can do…
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Study start
•Very insulin resistant high 
insulin requirements (~2-3x other 
trial patients)
•High insulin rates  greater risk 
of hypo events, thus the 
stochastic model forecasts drove 
BG control
•Controller targeted ~7 mmol/L, 
based on possible change in 
insulin sensitivity in the future
•In essence, stochastic model said 
that 95th percentile rise in insulin 
sensitivity would lead to a BG < 4 
mmol/L so target (median) was 
raised to ~7mmol/L to guarantee 
safety (5% max risk of BG < 4) 
automatically
•Here we have the first ~10 hours 
of the trial…
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•Two hours later, and baby is 
still very insulin resistant.
•Controller targeting 7 mmol/L 
(to keep bottom of green 
shaded area at 4 mmol/L)…
•Thus, a 5% maximum risk of 
getting a BG < 4 mmol/L for a 
given 2-3 hourly intervention
Patient G
0 5 10 15 20 25 30 35
0
5
10
15
B
G
 (
m
m
o
l/
L
)
Patient G
0 5 10 15 20 25 30 35
0
0.1
0.2
0.3
0.4
U
/k
g
/h
r
0
5
10
m
g
/k
g
/m
in
0 5 10 15 20 25 30 35
0
1
2
x 10
-3
L
/[
m
U
.m
in
]
Time [hours]
Study start
•Baby still very insulin resistant…
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•Baby still very insulin resistant…
Patient G
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Study start •Sudden BG drop of ~2 
mmol/L
•If insulin infusions had 
been more ‘aggressive’, 
may have caused a 
hypo event  tolerated 
period of higher BG to 
create buffer against 
hypo.
•No clinically observable 
change in baby over 
this time  something 
inside ‘switched on’
•Stochastic model 
forecasts to account for 
un-measurable and un-
modelled effects
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Time on insulin
Study period
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Dextrose infusion
Trial within total insulin period
•Change in insulin 
sensitivity contained
•Insulin infusion rate 
adjusted
•Rebound 
hyperglycaemia when 
insulin stopped
In Summary:
• SPRINT 
– Successful in reducing mortality, organ failure and cost = 240 lives and 
$2M over last 4 years
– Model derived, but implemented in paper
– Not adaptive to clinical needs or practice
• The Future: Flexible, stochastic, targeted and thus customisable 
across cohorts and practices
– But, equally effective
– Coming in 2010! (already here if you are a <1kg neonate in Chch)
• The Moral: It’s not the car, it’s how you drive it!
– Anyone can drive a Ferrari F1 car, but only Michael Schumacher can 
control it and win world championships!
– I.e. it’s not the therapy or the target, it’s the protocol or how you do it that 
defines success  protocolised computer based TGC can make everyone 
an expert!
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